leuprolide and elagolix

To assess the cost-effectiveness of elagolix versus leuprolide acetate in women with moderate to severe endometriosis pain.. A Markov model was developed. The efficacy of leuprolide acetate was derived from statistical prediction models using elagolix trial data. Model inputs were extracted from Phase III clinical trials and published literature.. Compared with leuprolide acetate, elagolix generated positive net monetary benefit (NMB) assuming a payer's willingness-to-pay threshold of US$100,000 per quality-adjusted life year over a 1-year time horizon: US$5660 for elagolix 150 mg and US$6443 for elagolix 200 mg. The 2-year NMBs were also positive.. Elagolix was cost effective versus leuprolide acetate in the management of moderate to severe endometriosis pain over 1- and 2-year time horizons. Results were robust in sensitivity analyses.

Topics: Adolescent; Adult; Cost-Benefit Analysis; Endometriosis; Female; Fertility Agents, Female; Humans; Hydrocarbons, Fluorinated; Leuprolide; Markov Chains; Middle Aged; Models, Economic; Pain; Pyrimidines; Severity of Illness Index; United States; Young Adult

We evaluated elagolix and leuprolide from the patient's perspective for the treatment of endometriosis-related pain.. Preference weights from a published discrete choice experiment were used to evaluate preferences for treatment profiles simulating elagolix (150 mg/day and 200 mg/twice-daily dosages) and leuprolide for the treatment of moderate to severe endometriosis-related pain. Sensitivity analyses were conducted by varying the range of risk for pregnancy-related problems, moderate to severe hot flashes, and bone fracture across scenarios.. The 200 mg twice daily dosage of elagolix is more likely to be preferred over leuprolide by patients with moderate to severe endometriosis-related pain in all scenarios explored in the evaluation and sensitivity analyses. The probability that an average respondent would select a treatment was sensitive to increases in risk of moderate to severe hot flashes for leuprolide and possible variations in the risk of pregnancy-related problems for both treatments but was not influenced by an increased risk of bone fracture.. Patients' preferences for treatment of endometriosis-related pain should be evaluated using the benefits and risks of each pharmacological option. Respondents were more likely to prefer the treatment profile similar to 200 mg twice daily elagolix over that of leuprolide in all scenarios.

Topics: Adolescent; Adult; Choice Behavior; Endometriosis; Female; Humans; Hydrocarbons, Fluorinated; Leuprolide; Middle Aged; Pain; Patient Preference; Pregnancy; Pregnancy Complications; Pyrimidines; Severity of Illness Index; Surveys and Questionnaires; United States; Young Adult